Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Above Fifty Day Moving Average – Time to Sell?

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $16.22 and traded as high as $17.30. Aurinia Pharmaceuticals shares last traded at $16.73, with a volume of 1,031,788 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada raised their price objective on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.67.

Aurinia Pharmaceuticals Trading Down 1.3%

The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. The business’s 50 day simple moving average is $16.23 and its 200 day simple moving average is $15.97. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of 7.21 and a beta of 1.60.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The firm had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.90 EPS for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AUPH. State of Alaska Department of Revenue grew its stake in shares of Aurinia Pharmaceuticals by 129.1% during the 3rd quarter. State of Alaska Department of Revenue now owns 19,570 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 11,027 shares during the period. GAMMA Investing LLC boosted its stake in shares of Aurinia Pharmaceuticals by 22.2% during the 3rd quarter. GAMMA Investing LLC now owns 5,317 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 967 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter worth approximately $60,000. IFP Advisors Inc boosted its holdings in Aurinia Pharmaceuticals by 10.3% in the second quarter. IFP Advisors Inc now owns 361,634 shares of the biotechnology company’s stock worth $6,137,000 after purchasing an additional 33,843 shares during the period. Finally, Allworth Financial LP grew its position in shares of Aurinia Pharmaceuticals by 34.9% during the 2nd quarter. Allworth Financial LP now owns 3,307 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 855 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada.